Altimmune, Inc. (ALT) faces securities class action lawsuit

Altimmune, Inc. (ALT) is facing a securities class action lawsuit filed by Levi & Korsinsky on behalf of shareholders. The complaint alleges that Altimmune made false and misleading statements regarding the results of its Phase 1/2 clinical trials for its intranasal COVID-19 vaccine candidate known as AdCOVID.

According to the lawsuit, Altimmune claimed that AdCOVID was well-tolerated and generated a strong immune response in the clinical trials. However, it is alleged that the company failed to disclose crucial information about the vaccine’s efficacy, including the fact that it failed to meet its primary endpoint of demonstrating a “statistically significant immune response.”

The complaint further alleges that Altimmune’s statements regarding the vaccine’s potential for emergency use authorization (EUA) from the FDA were also misleading. The company allegedly overstated the vaccine’s prospects for obtaining EUA, causing its stock price to be artificially inflated.

As a result of these alleged misrepresentations, Altimmune’s stock price fell dramatically when the truth about the vaccine’s efficacy came to light. Shareholders who purchased Altimmune stock during the relevant period suffered financial losses as a result of the company’s alleged wrongdoing.

Levi & Korsinsky, a national securities litigation firm, is representing shareholders in the class action lawsuit against Altimmune. The firm is seeking to recover losses on behalf of investors who purchased Altimmune stock between May 18, 2021, and August 12, 2021.

Investors who are interested in joining the lawsuit or learning more about their legal rights and options in this case are encouraged to contact Levi & Korsinsky. The firm specializes in representing shareholders in securities fraud, corporate governance, and merger and acquisition litigation.

The securities class action lawsuit against Altimmune serves as a reminder of the importance of transparency and honesty in the biopharmaceutical industry. Companies must provide accurate and complete information to investors to ensure the integrity of the market and protect shareholders from financial harm.

In conclusion, the allegations against Altimmune highlight the risks that investors face when companies make misleading statements about their products and prospects. Shareholders who believe they have been harmed by Altimmune’s alleged misconduct have the option to seek legal recourse through the securities class action lawsuit. Levi & Korsinsky is committed to helping investors recover their losses and hold companies accountable for any misleading or deceptive practices that may harm shareholders.